The global human microbiome market is expected to grow from USD 488.99 million 2017 to USD 1,985.68 million by the end of 2024 at a Compound Annual Growth Rate (CAGR) of 22.16%.

"Increased focus on human microbiome therapy
is one of the factors largely attributing to the growth of human microbiome market globally"

The factors attributing to the growth of the market are increased focus on human microbiome therapy, and human microbiome for drug development, early disease detection, and diagnosis. However, some factors such as and limited expertise and lack of comprehensive research may hinder the market growth. The global human microbiome market is expected to showcase the opportunities such as increasing collaborations and research investments to create growth opportunities, and development of human microbiome therapeutic products. In the near future, the market may face the possible challenges in the growth due to and causal links between microbiota dysbiosis and disease. However, the key players in the market are putting regressive efforts to provide innovative offerings and benchmark strategies in the global human microbiome market market."Acute Diarrhea: The highest growing disease for the global human microbiome market"

On the basis of disease, the global human microbiome market is studied across Acute Diarrhea, Autoimmune Disorders, Cancer, Diabetes, Mental Disorders, and Obesity. Among all these disease, the Acute Diarrhea is projected to hold the largest market share while the Cancer has the potential to grow the market with the highest CAGR in the forecast period."Prebiotics: The highest growing product for the global human microbiome market"

On the basis of product, the global human microbiome market is studied across Diagnostic Devices, Drugs, Foods, Medical Foods, Prebiotics, and Probiotics. Among all these product, the Prebiotics is projected to hold the largest market share while the Drugs has the potential to grow the market with the highest CAGR in the forecast period."Metagenomic Sequencing: The highest growing technology for the global human microbiome market"

On the basis of technology, the global human microbiome market is studied across 16s rRNA Sequencing, Cell Culture Technology, Computational Tools, High-Throughput Technology, Metagenomic Sequencing, and Omics Technology. Among all these technology, the Metagenomic Sequencing is projected to hold the largest market share while the 16s rRNA Sequencing has the potential to grow the market with the highest CAGR in the forecast period."Gastrointestinal Disorders: The highest growing theuraptic area for the global human microbiome market"

On the basis of theuraptic area, the global human microbiome market is studied across Gastrointestinal Disorders, Metabolic Disorders, Skin Disorders, and Women's Health. Among all these theuraptic area, the Gastrointestinal Disorders is projected to hold the largest market share while the Skin Disorders has the potential to grow the market with the highest CAGR in the forecast period."Therapeutics: The highest growing application for the global human microbiome market"

On the basis of application, the global human microbiome market is studied across Diagnostics and Therapeutics. Among all these application, the Therapeutics has captured the maximum market share while the Diagnostics has the opportunity to emerge with the highest CAGR."Americas: The highest growing geography for the global human microbiome market"

On the basis of geography, the global human microbiome market is studied across Americas, (United States, Brazil, Canada, Mexico, and Argentina) Europe, Middle East & Africa, (United Kingdom, Germany, France, Saudi Arabia, United Arab Emirates, Italy, and Russia) and Asia-Pacific (China, Japan, India, and Australia). Among all these geography, the Asia-Pacific is showing the maximum growth in the near future with the highest CAGR while the Americas is dominating the market with highest market size.

"DuPont: The potential growing player for the global human microbiome market"

The key players profiled in the global human microbiome market are DuPont, E.I. Du Pont De Nemours and Company, Enterome Bioscience, Merck & Co., Inc., Metabiomics Corporation, Microbiome Therapeutics, LLC, Osel, Inc., Second Genome, Inc., Seres Therapeutics, Synthetic Biologics Inc., Vedanta Biosciences, Inc., Vithera Pharmaceuticals, and Yakult Honsha Co., Ltd..


The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players in the global human microbiome market.
2. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments in the global human microbiome market.
3. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets for the global human microbiome market.
4. Market Diversification: Provides detailed information about new products launches, untapped geographies, recent developments, and investments in the global human microbiome market.
5. Competitive Assessment & Intelligence: Provides exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the global human microbiome market.